These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11996401)

  • 1. The association between respiratory syncytial virus infection and reactive airway disease.
    Piedimonte G
    Respir Med; 2002 Apr; 96 Suppl B():S25-9. PubMed ID: 11996401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants.
    Young J
    Respir Med; 2002 Apr; 96 Suppl B():S31-5. PubMed ID: 11996402
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
    Simões EA; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick L; Groothuis JR;
    J Allergy Clin Immunol; 2010 Aug; 126(2):256-62. PubMed ID: 20624638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Asthma and respiratory syncytial virus. New opportunities for therapeutic intervention].
    Mejías A; Chávez-Bueno S; Ríos AM; Fonseca-Aten M; Gómez AM; Jafri HS; Ramilo O
    An Pediatr (Barc); 2004 Sep; 61(3):252-60. PubMed ID: 15469810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus infection: clinical features, management, and prophylaxis.
    Greenough A
    Curr Opin Pulm Med; 2002 May; 8(3):214-7. PubMed ID: 11981311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.
    Null D; Pollara B; Dennehy PH; Steichen J; Sánchez PJ; Givner LB; Carlin D; Landry B; Top FH; Connor E
    Pediatr Infect Dis J; 2005 Nov; 24(11):1021-3. PubMed ID: 16282947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches.
    Openshaw PJ; Dean GS; Culley FJ
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S58-64; discussion S64-5. PubMed ID: 12671454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial.
    Scheltema NM; Nibbelke EE; Pouw J; Blanken MO; Rovers MM; Naaktgeboren CA; Mazur NI; Wildenbeest JG; van der Ent CK; Bont LJ
    Lancet Respir Med; 2018 Apr; 6(4):257-264. PubMed ID: 29500030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics).
    Canfield SD; Simoes EA
    Pediatr Ann; 1999 Aug; 28(8):507-14. PubMed ID: 10483596
    [No Abstract]   [Full Text] [Related]  

  • 13. Respiratory syncytial virus prophylaxis--the story so far.
    Simoes EA; Groothuis JR
    Respir Med; 2002 Apr; 96 Suppl B():S15-24. PubMed ID: 11996400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
    Blanken M; Rovers M; Sanders E; Bont L
    Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
    Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
    J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus infection and recurrent wheezing: what next?
    Puddu M; Fanos V
    J Chemother; 2007 Oct; 19 Suppl 2():8-11. PubMed ID: 18073170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.